GSK plc
GSK
$38.40
$0.441.16%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -8.94% | -0.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.94% | -0.30% | |||
| Cost of Revenue | -25.42% | 7.25% | |||
| Gross Profit | -1.44% | -3.39% | |||
| SG&A Expenses | -22.88% | -31.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -247.52% | 161.83% | |||
| Total Operating Expenses | -28.15% | -4.60% | |||
| Operating Income | 128.26% | 47.10% | |||
| Income Before Tax | 268.23% | 765.73% | |||
| Income Tax Expenses | 432.97% | 6,201.65% | |||
| Earnings from Continuing Operations | 247.84% | 658.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -67.30% | 30.39% | |||
| Net Income | 285.78% | 802.46% | |||
| EBIT | 128.26% | 47.10% | |||
| EBITDA | 101.77% | -7.00% | |||
| EPS Basic | 285.14% | 802.16% | |||
| Normalized Basic EPS | 169.86% | 104.35% | |||
| EPS Diluted | 284.32% | 796.22% | |||
| Normalized Diluted EPS | 170.89% | 104.12% | |||
| Average Basic Shares Outstanding | 0.17% | 0.02% | |||
| Average Diluted Shares Outstanding | -0.19% | 0.10% | |||
| Dividend Per Share | -1.66% | 4.97% | |||
| Payout Ratio | -0.75% | 1.14% | |||